FDAAA and labeling
Former FDAer Greg Burkhart, Burkhart & Freiman, proposes that one aspect of newfound authority that FDA will embrace is the ability to mandate product labeling changes. "You're going to see something a little bit different regarding how safety information may get into the label. There is going to a much bigger push I think coming from certain parts of the agency. It's going to be very difficult for the divisions ... to resist such changes," he said at the DIA session. Disagreements within FDA over the appropriate treatment of safety information have recently been exposed to the public (1"The Pink Sheet" Aug. 6, 2007, p. 6). "It will change the way that the sponsors are notified when FDA thinks something is going on. Before it had to have a high threshold before FDA would even bother because a lot of times there would be a fight. I don't think that is going to be the case anymore. I think things are going to get into the label now from the FDA viewpoint that may have a lower threshold"...
You may also be interested in...
Political pressure from FDA outsiders interested in improving drug safety oversight may have backfired, resulting in an embarrassing advisory committee meeting for the agency. The July 30 review of a cardiovascular safety signal for GlaxoSmithKline's diabetes drug Avandia became a forum to play out another controversy between the Office of New Drugs and the Office of Surveillance and Epidemiology
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.